1
|
Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fernández de Misa-Cabrera R, Peñate-Santana Y, Hernandez-Machin B, Estrach-Panella T, Llamas-Velasco M, Yanguas-Bayona JI, Morillo-Andujar M, Acebo-Mariñas E, Perez-Gala S, Armario-Hita JC, Sanchez-Sambucety P, Ortiz-Brugues A, Eguren-Michelena C, Bielsa-Marsol I, Lopez-Pestaña A, Blanes-Martinez M, Fernandez-Guarino M, Lopez-Lerma I. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas. Actas Dermosifiliogr 2024:S0001-7310(24)00358-2. [PMID: 38653368 DOI: 10.1016/j.ad.2024.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 12/04/2023] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combinationwith other therapies at 19 tertiary referral teaching hospitals. RESULTS A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported. CONCLUSIONS Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
Collapse
Affiliation(s)
| | | | | | | | | | - Y Peñate-Santana
- Hospital Universitario Basurto, Bilbao, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital de Bellvitge, Barcelona, Spain; Red Canaria de Linfomas, Spain; Hospital Clinic de Barcelona, Spain; Hospital La Princesa, Madrid, Spain; Complejo Hospitalario Navarra, Pamplona, Spain; Hospital Virgen del Rocío, Sevilla, Spain; Hospital Universitario Cruces, Barakaldo, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Universitario del Puerto Real, Cadiz, Spain; Hospital Universitario de León, Spain; Hospital Arnau y Vilanova, Lérida, Spain; Hospital Infanta Leonor, Madrid, Spain; Hospital German Trias y Pujol, Barcelona, Spain; Hospital Universitario Donostia, San Sebastián, Spain; Hospital de Alicante, Spain; Hospital Cruz Roja, Madrid, Spain; Hospital Vall D´Hebrón, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fernández de Misa-Cabrera R, Peñate Y, Hernandez-Machin B, Estrach-Panella T, Llamas-Velasco M, Yanguas-Bayona JI, Morillo-Andujar M, Acebo-Mariñas E, Perez-Gala S, Armario-Hita JC, Sanchez-Sambucety P, Ortiz-Brugues A, Eguren-Michelena C, Bielsa-Marsol I, Lopez-Pestaña A, Blanes-Martinez M, Fernandez-Guarino M, Lopez-Lerma I. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas. Actas Dermosifiliogr 2024:S0001-7310(24)00160-1. [PMID: 38395224 DOI: 10.1016/j.ad.2023.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 11/27/2023] [Accepted: 12/04/2023] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combination with other therapies at 19 tertiary referral teaching hospitals. RESULTS A total of 133 men (62%) and 83 women (38%) were included, with a mean age of 63.5 year (27-95). A total of 45% were on bexarotene monotherapy for the entire study period, 22% started on bexarotene but eventually received an additional therapy, 13% were on another treatment but eventually received bexarotene while the remaining 20% received a combination therapy since the beginning. The median course of treatment was 20.78 months (1-114); and the overall response rate, 70.3%. Complete and partial response rates were achieved in 26% and 45% of the patients, respectively. Treatment was well tolerated, being the most common toxicities hypertriglyceridemia (79%), hypercholesterolemia (71%), and hypothyroidism (52%). No treatment-related grade 5 adverse events were reported. CONCLUSIONS Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.
Collapse
Affiliation(s)
| | | | | | | | | | - Y Peñate
- Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M, Rivera R, Carrascosa JM, de la Cueva-Dovao P, Armesto-Santos S, Ruíz-Villaverde R, Velasco-Pastor M, Magdaleno-Tapial J, Yanguas-Bayona JI, Ribera-Pibernat M, Salgado-Boquete L, Herranz-Pinto P, Romero-Mate A, Martínez-Lorenzo E, López-Estebaranz JL, Ballescá-López F, Botella-Estrada R. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population. Australas J Dermatol 2023; 64:e317-e326. [PMID: 37435962 DOI: 10.1111/ajd.14130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 03/26/2023] [Accepted: 06/26/2023] [Indexed: 07/13/2023]
Abstract
BACKGROUND AND OBJECTIVE The data in clinical practice regarding the effectiveness and safety of brodalumab in psoriasis are scarce, especially at scalp and palmoplantar locations. The main objective was the percentage of patients achieving absolute PASI ≤3/ ≤1/ =0 for plaque psoriasis and the percentage of patients achieving an IGA 0-1/IGA 0 for the special locations at Week 52 of treatment. PATIENTS AND METHODS Observational retrospective multicentre study in 28 Spanish Hospitals that included adult patients with plaque psoriasis treated with brodalumab, from September 2018 until March 2021. RESULTS A total of 200 patients were included. The mean baseline PASI was 10.97 (±6.28) with a mean basal scalp (n = 58) and palmoplantar (n = 40) IGA of 2.10 (±0.97) and 2.15 (±1.26), respectively. At Week 52, 93.98%/75.90%/68.67% of patients reached an absolute PASI ≤3/ ≤1/ =0 in plaque psoriasis (n = 83), with a percentage of patients achieving scalp (n = 27) and palmoplantar (n = 19) IGA 0-1/IGA 0 of 96.3%/88.9% and 100%/88.9%, respectively. Fifteen per cent of patients reported any adverse events with candidiasis being the most reported (6%), but only 6% of the adverse events required the withdrawal. CONCLUSIONS Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis.
Collapse
Affiliation(s)
- A Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M Hospital-Gil
- Department of Dermatology, Hospital Universitario Puerta del Hierro, Madrid, Spain
| | - E Vilarrasa-Rull
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Llamas-Velasco
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain
| | - R Rivera
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - P de la Cueva-Dovao
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - S Armesto-Santos
- Department of Dermatology, Hospital Universitario Marques De Valdecilla, Santander, Spain
| | - R Ruíz-Villaverde
- Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain
| | - M Velasco-Pastor
- Department of Dermatology, Hospital Arnau de Vilanova, Valencia, Spain
| | - J Magdaleno-Tapial
- Department of Dermatology, Consorcio Hospital General Universitario de Valencia, Spain
| | | | - M Ribera-Pibernat
- Department of Dermatology, Hospital Universitari Parc Tauli de Sabadell, Barcelona, Spain
| | - L Salgado-Boquete
- Deparment of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - P Herranz-Pinto
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
| | - A Romero-Mate
- Department of Dermatology, Hospital Universitario de Fuenlabrada, Madrid, Spain
| | - E Martínez-Lorenzo
- Department of Dermatology, Hospital Universitario Virgen de la Salud, Toledo, Spain
| | | | | | - R Botella-Estrada
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- Facultad de Medicina, Universidad de Valencia, Valencia, Spain
| |
Collapse
|
4
|
Fernández-Parrado M, Arostegui-Aguilar J, Perandones-González H, Hiltun I, de Dot-Gómara T, Larra-García M, Yanguas-Bayona JI. Photodynamic therapy in uncommon forms of lichen planus. Dermatol Ther 2022; 35:e15914. [PMID: 36209380 DOI: 10.1111/dth.15914] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Revised: 09/20/2022] [Accepted: 10/06/2022] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | - Ingrid Hiltun
- Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
| | - Teresa de Dot-Gómara
- Department of Pathology, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
| | - Mónica Larra-García
- Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Navarra, Spain
| | | |
Collapse
|
5
|
Loidi-Pascual L, Lecumberri-Biurrun MJ, Arozarena-Martinicorena I, Goñi-Gironés E, Yanguas-Bayona JI. Study of cutaneous melanoma recurrences after sentinel node biopsy: Patterns of dissemination and use of complementary test in follow-up. Eur J Cancer Care (Engl) 2020; 30:e13344. [PMID: 33089896 DOI: 10.1111/ecc.13344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Revised: 07/06/2020] [Accepted: 08/07/2020] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To investigate the patterns of melanoma recurrence in the local population, including factors that may influence in this event and timing of relapse, and to determine the mode of detection of them. METHODS This is a retrospective cohort study of patients with melanoma who underwent sentinel lymph node biopsy at the Complejo Hospitalario de Navarra (Spain) from 2002 to 2012. The following data were collected of each patient: age, gender, date of diagnosis, location of melanoma, histological subtype, Breslow thickness, ulceration, mitosis, sentinel node status, AJCC 8th edition stage, site of first diagnosed metastasis, mode of relapse, date of first relapse and time of death. RESULTS Of 308 patients, 30% people suffered metastasis. The mean follow-up time was 68.63 months. 51.1% of relapses were locoregional and 48.9% haemato-visceral. Sentinel node status was the only variable associated with higher risk of haemato-visceral metastasis (p < 0.001). The mean time between diagnosis of melanoma and recurrence was 2.7 years. Most recurrences were detected by the patient himself or had any type of symptoms and were consequently selected for a complementary test. CONCLUSION It is important to follow-up all patients with diagnosis of cutaneous melanoma, essentially during the first 5 years after diagnosis.
Collapse
Affiliation(s)
| | | | | | - Elena Goñi-Gironés
- Nuclear Medicine Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | | |
Collapse
|
6
|
Oscoz-Jaime S, Azcona-Rodríguez M, Yanguas-Bayona JI. Squamous Cell Carcinoma on a Port Wine Stain. Actas Dermosifiliogr (Engl Ed) 2019; 110:e1-e2. [PMID: 31202472 DOI: 10.1016/j.ad.2018.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Revised: 01/17/2018] [Accepted: 01/17/2018] [Indexed: 11/18/2022] Open
Affiliation(s)
- S Oscoz-Jaime
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
| | - M Azcona-Rodríguez
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
| | - J I Yanguas-Bayona
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
| |
Collapse
|
7
|
Agulló-Pérez AD, Resano-Abarzuza MÁ, Córdoba-Iturriagagoitia A, Yanguas-Bayona JI. Porokeratotic eccrine and hair follicle nevus: a report of two cases and review of the literature. An Bras Dermatol 2017; 92:121-125. [PMID: 29267468 PMCID: PMC5726699 DOI: 10.1590/abd1806-4841.20176536] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Accepted: 11/25/2016] [Indexed: 12/03/2022] Open
Abstract
Porokeratotic eccrine and hair follicle nevus is a very rare non-hereditary
disorder of keratinization with eccrine and hair follicle involvement with only
9 cases described in the literature. In 2009 the term porokeratotic anexial
ostial nevus was proposed to comprehend porokeratotic eccrine and hair follicle
nevus and a related and more common process without follicular involvement:
porokeratotic eccrine ostial and dermal duct nevus Recent findings suggest that
both entities may be produced by a mutation in GJB2 gene, which is associated to
KID syndrome. Herein we report 2 cases of porokeratotic eccrine and hair
follicle nevus and review the existing cases in the Spanish and English
literature.
Collapse
Affiliation(s)
- Alfredo Daniel Agulló-Pérez
- Department of Dermatology, Hospital IMED Levante - Benidorm, Spain.,Department of Dermatology, Complejo Hospitalario de Navarra - Pamplona, Spain
| | | | | | | |
Collapse
|
8
|
Oscoz-Jaime S, Agulló-Pérez AD, Llanos-Chavarri C, Yanguas-Bayona JI. Cutaneous Infiltration due to Waldenström Macroglobulinemia. Actas Dermosifiliogr (Engl Ed) 2017; 109:75-78. [PMID: 28784233 DOI: 10.1016/j.ad.2017.04.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2016] [Revised: 04/17/2017] [Accepted: 04/18/2017] [Indexed: 10/19/2022] Open
Affiliation(s)
- S Oscoz-Jaime
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona (Navarra), España.
| | - A D Agulló-Pérez
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona (Navarra), España
| | - C Llanos-Chavarri
- Servicio de Anatomía Patológica, Complejo Hospitalario de Navarra, Pamplona (Navarra), España
| | - J I Yanguas-Bayona
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona (Navarra), España
| |
Collapse
|
9
|
Oscoz-Jaime S, Loidi-Pascual L, Tuñón-Álvarez MT, Yanguas-Bayona JI. Lichen Nitidus Arising on Vitiligo: A New Variant of the Isotopic Coresponse. Actas Dermosifiliogr 2016; 107:860-861. [PMID: 27372544 DOI: 10.1016/j.ad.2016.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Revised: 05/11/2016] [Accepted: 05/29/2016] [Indexed: 11/24/2022] Open
Affiliation(s)
- S Oscoz-Jaime
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
| | - L Loidi-Pascual
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
| | - M T Tuñón-Álvarez
- Servicio de Anatomía Patológica, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
| | - J I Yanguas-Bayona
- Servicio de Dermatología, Complejo Hospitalario de Navarra, Pamplona, Navarra, España
| |
Collapse
|